We describe the case report and detailed operative findings of a 57-year-old man who underwent radical retropubic prostatectomy (RRP) for incidental prostate cancer 2 weeks after open prostatectomy for benign prostatic hyperplasia (BPH). We advocate an open cystotomy at the time of RRP to identify the ureters and assure that the bladder neck margin is free of prostatic tissue. We offer this therapy as a safe curative treatment modality in the early postoperative period after prior prostate surgery.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Incidence and Risk of Thromboembolic and Cardiovascular Adverse Events with PARP Inhibitor Treatment in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Safety Meta-analysis.
Eur Urol Open Sci
February 2025
Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy.
Background And Objective: PARP inhibitor (PARPi) treatment is an effective option for patients with metastatic castration-resistant prostate cancer (mCRPC). There are few data on the cardiovascular and thromboembolic safety of these agents in mCRPC, as cardiovascular and thromboembolic adverse events (AEs) are uncommon. Our aim was to analyze the incidence and risk of major adverse cardiovascular events (MACEs), thromboembolic events, and hypertension with PARPi therapy in mCRPC.
View Article and Find Full Text PDFUnveiling hotspots of emerging research in the miRNA-related mechanism underlying cancer through comprehensive bibliometric analysis with implications for precision medicine and non-invasive diagnostics.
Front Oncol
January 2025
Department of Colorectal Hernia Surgery, Binzhou Medical University Hospital, Binzhou, Shandong, China.
Background And Objective: MicroRNAs (miRNAs) are implicated in cancer by exerting roles in tumor growth, metastasis, and even drug resistance. The general trends of miRNA research in diverse cancers are not fully understood. In this work, miRNA-related research in colorectal cancer, prostate cancer, leukemia, and brain tumors was analyzed in search of key research trends with clinical potential.
View Article and Find Full Text PDFGut microbiota, metabolites, and cytokines in relation to the risk of prostate cancer in the Asian population.
Front Oncol
January 2025
Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Purpose: Studies have shown that gut microbiota is involved in the tumorigenesis and development of prostate cancer. We aimed to perform a comprehensive analysis of causal associations of gut microbiota, metabolites, and cytokines with prostate cancer in the Asian population.
Patients And Methods: Genome-wide association study (GWAS) summary datasets were collected from the public databases.
Correction to: Dual Radionuclide Therapy: The Synergistic Effects of [Tb]Tb-PSMA and [Lu]Lu-PSMA in Advanced Prostate Cancer Post [Lu]Lu-PSMA Failure.
Nucl Med Mol Imaging
February 2025
Department of Nuclear Medicine and PET/CT, King Hussein Cancer Center (KHCC), 11941 Al-Jubeiha, Amman, Jordan.
[This corrects the article DOI: 10.1007/s13139-024-00871-4.].
View Article and Find Full Text PDFExploring the Correlation Between Multiparameters Detected in Primary Prostate Cancer using F‑18 PSMA‑1007 PET/MRI and their Potential for Predicting Metastasis.
Nucl Med Mol Imaging
February 2025
National Cyclotron and PET Centre, Chulabhorn Hospital, 906 Kamphaeng Phet 6 Rd., Talat Bang Khen, Lak Si, Bangkok, 10210 Thailand.
Purpose: Prostate-specific membrane antigen (PSMA) Positron emission tomography/magnetic resonance imaging (PET/MRI) surpasses conventional MRI (cMRI) in prostate cancer (PCa) evaluation. Our objective is to evaluate correlation of quantitative parameters in PCa using Fluorine-18 (F-18) PSMA-1007 PET/MRI and their potential for predicting metastases.
Methods: This retrospective study included 51 PCa patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!